Bile Duct Cancer Treatment Market Demand, Recent Developments, Company Profile Analysis and Growth Opportunity Forecast Report 2022-2029

“Bile Duct Cancer Treatment Market | DataM Intelligence »

Key players in the Bile Duct Cancer Treatment market include ConMed Corporation, Bristol-Myers Squibb, Johnson & Johnson, Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Incyte Corporation, Celgene Corp, Bayer AG, Boston Scientific Corporation and large companies. presented in the final report

Bile Duct Cancer Treatment Market Outlook:

According to research report published by DataM Intelligence, the global Bile Duct Cancer Treatment market size is expected to reach USD 1 Billion by the end of 2029, growing at a CAGR of 9.2% during the forecast period 2022-2029.

Bile duct cancer, also known as cholangiocarcinoma, forms in the thin tubes (bile ducts) that carry bile from the digestive fluid. The bile ducts connect the liver to the gallbladder and the small intestine. It mainly occurs in people over 50, although it can occur at any age. The specific causes of bile duct cancer are unknown.

However, a few factors responsible for the development of bile duct cancer are long-term inflammation of the liver, gallstones, bile duct abnormalities such as cysts, liver fluke parasite infection which mainly causes infection bile ducts leading to cancer, and exposure to harmful chemicals and toxins. The main symptoms associated with bile duct cancer include jaundice, weight loss, loss of appetite, discoloration of urine and stool, abdominal pain, itching and fever. Bile duct cancer is treated with chemotherapy, surgery, radiation therapy, targeted therapy, and others.

Report statistics:



Market CAGR


The biggest market

North America

Fastest growing market

Asia Pacific

Market segmentation

By type of cancer, by type of treatment, by end users and by region

Report covered

Methodology and Scope, Industry Analysis, COVID-19 Analysis, Regional Analysis, Competitive Landscape and Company Profile Analysis.

Global growth in bile duct cancer (cholangiocarcinoma) treatment is driven by increasing prevalence of bile duct cancers worldwide, growing geriatric population, changing lifestyles and increased smoking habits ; Rising investment in research and development activities are the major factors driving the market.

Information on regional shares:

Bile duct cancer, also known as cholangiocarcinoma, is spreading widely in Southeast Asia. The high consumption of raw fish in the Asia-Pacific (APAC) region drives the incidence of liver fluke infections, thereby stimulating bile duct cancer. Increased industrialization is also attributed to growth in the APAC region, as exposure to harmful printing chemicals is high among industrial workers in countries like China, Japan, and India. For example, Eisai Co., Ltd – A Phase 2 trial of E7090 in subjects with unresectable advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor (FGFR) 2 gene fusion.

North America holds the world’s second largest market for bile duct cancer due to high cancer incidence, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide . The World Cancer Report predicts that the incidence rate of new cancer cases will increase by 50% to reach 15 million in 2020. The existence of a highly developed health system, the high degree of acceptance by practicing physicians of new methods of chemotherapy and photodynamic therapy, the full availability of advanced technological tools, FDA approval of new drugs, as well as the presence of a large number of organizations engaged in R&D activities related to cancer vaccines.

Download Sample Brochure @

Impact of COVID-19 on the industry:

The COVID-19 pandemic has had a negative impact on healthcare systems around the world and on the vulvar cancer market. The Centers for Disease Control and Prevention (CDC) and many medical professional organizations have recommended that cancer screening and other preventative health services, as well as elective surgeries, be postponed unless the risks pose it. outweigh the benefits and only secure hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has also had an impact on ongoing clinical trials. However, the situation should gradually improve.

Market Segmentation Overview:

On the basis of cancer type, the global bile duct cancer (cholangiocarcinoma) treatment market is segmented into intrahepatic bile duct cancer and extrahepatic bile duct cancer. Intrahepatic bile duct cancer arises in the bile ducts of the liver and is sometimes classified as a type of liver cancer. This type accounts for 5 to 10% of cases.

Extrahepatic bile duct cancer: This type occurs more often and is more treatable and can form in either of two areas. The hilum area, where your left and right bile ducts join to form the common hepatic duct. This is called perihilar cancer. Over 60% of the plethora of bile duct cancers fall into the category of perihilar bile duct cancers. The distal region, where your common bile duct passes through the pancreas. This is called distal cancer.

Chemotherapy (chemo) is treatment with cancer drugs usually given into a vein (IV) or taken by mouth. These drugs enter the bloodstream and reach all areas of the body, making them a useful treatment for certain cancers that have spread to organs beyond the bile ducts. Since the drugs reach all areas of the body, it is called systemic treatment. Drugs used in chemotherapy are 5-fluorouracil, gemcitabine, capecitabine, oxaliplatin, cisplatin and combination drug therapy. Factors such as the availability of a wide range of chemotherapeutic agents for the treatment of bile duct cancer and the ongoing innovative research combinations on improving chemotherapy by studying new drugs and drug combinations by through clinical trials are expected to drive the growth of the chemotherapy segment market over the forecast period.

Due to the growing patient population, the hospital segment held the largest market share. This is mainly due to the increasing number of patients suffering from diseases treated in hospitals with advanced infrastructure and adequate facilities. Moreover, the increasing number of hospitals and adequate reimbursement policies are also contributing to the growth of this segment. Additionally, medications can be given intravenously and surgery is performed under the supervision of medical practitioners at these locations.

Inquire Before Buying Full Report @

Competitive landscape and major companies featured:

Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market is quite competitive with some key competitors such as ConMed Corporation, Bristol-Myers Squibb, Johnson & Johnson, Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Incyte Corporation , Celgene Corp, Bayer AG and Boston Scientific Corporation. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the market globally. For example, Incyte Corporation-A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants with Unresectable or Metastatic Cholangiocarcinoma.

Market segmentation :

By type of cancer:

Intrahepatic bile duct cancer

Extrahepatic bile duct cancer


By type of treatment:


Photodynamic therapy




By end users:



Cancer research institutes


The full report contains the information below.

  1. The report offers a comprehensive valuation of the market in terms of market value (USD) and annual growth rate (%). It does this by using in-depth qualitative insights, historical data (2020-2021) and verifiable projections of the market size over the forecast period (2022-2029).
  2. Visualize the composition of the Bile Duct Cancer Treatment market segmentation by cancer type, by treatment type, by end-user, and by region, highlighting major business assets and players.
  3. Identify business opportunities in the market by analyzing trends and co-development agreements.
  4. The report also covers data insights on various industry forces such as carrier’s five forces, regulations in each country, reimbursement scenario, technological advancements, PEST analysis, and price analysis.
  5. Excel data sheet with thousands of market level 4/5 segmentation data points.
  6. PDF report with the most relevant analysis convincingly assembled after exhaustive qualitative interviews and in-depth market research.
  7. Product mapping in Excel for key product of all major market players
  8. The report will provide access to approximately 50+ market data tables, over 40 figures and almost 180 pages.

Additional benefits after purchase:

  1. Unlimited Analyst Support for a period of 1 year.
  2. Any questions regarding the scope offered will be answered within 24-48 hours.
  3. An Excel sheet with market numbers will be provided separately

Media Contact
Company Name: DataM Intelligence
Contact person: Sai
E-mail: Send an email
Call: +1 877 441 4866
Country: United States